The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | The BILCAP study: a better overal survivial of biliary tract cancers with adjuvant capecitabine
Hendrik-Tobias Arkenau, MD, PhD of the Sarah Cannon Research Institute, Nashvile, TN, talks about one of the highlights from the gastrointestinal cancer session the ASCO 2017 meeting. The study, called the BILCAP study (ISRCTN72785446), looked at the whether patients with gallbladder colloidal carcinoma need to receive adjuvant chemotherapy or just supportive care, after their tumor is resected. This large phase III randomized study compared supportive care against capecitabine. This was the first large study to show that adjuvant chemotherapy leads to a better overall survival, with capecitabine resulting in a 15 months better overall survival compared to supportive care.
Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL
